Second generation antipsychotics in the treatment of bipolar depression: A systematic review and meta-analysis

Journal of Psychopharmacology

Volumn 26, Issue 5, 2012, Pages 603-617

  De Fruyt, Jürgen ^a,b   Deschepper, Ellen ^c   Audenaert, Kurt ^c   Constant, Eric ^d   Floris, Michel ^e   Pitchot, William ^f   Sienaert, Pascal ^b   Souery, Daniel ^g,h   Claes, Stephan ^b  

^a General Hospital St Jan   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e Department of Psychiatry   (Belgium)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^h Psy Pluriel European Center of Psychological Medicine   (Belgium)

Author keywords

Bipolar disorder; depressive episode; meta analysis; placebo; second generation antipsychotics

Indexed keywords

ARIPIPRAZOLE; FLUOXETINE; INOSITOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADULT; ADVERSE OUTCOME; AGED; AKATHISIA; ASTHENIA; BIPOLAR DEPRESSION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DYSKINESIA; DYSTONIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HUMAN; HYPERACTIVITY; HYPERKINESIA; HYPOKINESIA; MAJOR CLINICAL STUDY; MALE; MANIA; META ANALYSIS; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; MUSCLE RIGIDITY; OUTCOME ASSESSMENT; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SOMNOLENCE; STIFF NECK; SYSTEMATIC REVIEW; TREATMENT DURATION; TREMOR; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861795960     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111408461     Document Type: Review

References (48)

1. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression-lack of manic induction. J Affect Disord. 2005 ; 87: 121-130
2. Brown EB, McElroy SL, Keck PE, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006 ; 67: 1025-1033
3. Calabrese JR, Elhaj O, Gajwani P, Gao K. Clinical highlights in bipolar depression: focus on atypical antipsychotics. J Clin Psychiatry. 2005a ; 66: 26-33
4. Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005b ; 162: 1351-1360
5. Cookson J, Keck PE, Ketter TA, Macfadden W. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Int Clin Psychopharmacol. 2007 ; 22: 93-100
6. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008 ; 10: 788-797
7. Corya SA, Perlis RH, Keck PE, et al. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry. 2006 ; 67: 798-806
8. Cousins DA, Young AH. The armamentarium of treatments for bipolar disorder: a review of the literature. Int J Neuropsychopharmacol. 2007 ; 10: 411-431
9. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol. 2009 ; 13: 5-14
10. De Fruyt J, Demyttenaere K. Bipolar (spectrum) disorder and mood stabilization: standing at the crossroads?. Psychother Psychosom. 2007 ; 76: 77-88
11. Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry. 2007 ; 7: 40
12. El-Mallakh RS, Karippot A, Ghaemi SN Bipolar Depression. A Comprehensive Guide. El-Mallakh RS Ghaemi SN, ed. Arlington, VA: American Psychiatric Publishing ; 2007 :
13. Endicott J, Rajagopalan K, Minkwitz M, Macfadden W. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol. 2007 ; 22: 29-37
14. Fagiolini A, Chengappa KN, Soreca I, Chang J. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs. 2008 ; 22: 655-669
15. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009 ; 194: 4-9
16. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord. 2003 ; 5: 421-433
17. Healy D. Trussed in evidence? Ambiguities at the interface between clinical evidence and clinical practice. Transcult Psychiatry. 2009 ; 46: 16-37
18. Hirschfeld RM, Weisler RH, Raines SR, Macfadden W. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006 ; 67: 355-362
19. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996 ; 17: 1-12
20. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002 ; 59: 530-537
21. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003 ; 60: 261-269
22. Keck PE. Bipolar depression: a new role for atypical antipsychotics?. Bipolar Disord. 2005 ; 7: 34-40
23. Keck PE, Corya SA, Altshuler LL, et al. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J Clin Psychiatry. 2005 ; 66: 611-616
24. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008 ; 5: e45
25. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis J. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 ; 373: 31-41
26. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010 ; 71: 163-174
27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 ; 134: 382-389
28. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001 ; 158: 906-912
29. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007 ; 68: 20-27
30. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006 ; 163: 210-216
31. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007 ; 68: 826-831
32. Petitti DB. Approaches to heterogeneity in meta-analysis. Stat Med. 2001 ; 20: 3625-3633
33. Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry. 2007 ; 190: 287-292
34. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007 ; 356: 1711-1722
35. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007 ; 64: 442-455
36. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004 ; 65: 1715-1719
37. Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, et al. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther. 2004 ; 26: 125-134
38. Sienaert P, De Fruyt J Preventie van Bipolaire Stoornissen. Sienaert P De Fruyt J, ed. Mechelen: Wolters Kluwer Belgium ; 2007 :
39. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010 ; 121: 106-115
40. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008 ; 28: 13-20
41. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006 ; 26: 600-609
42. Tohen M, Calabrese J, Vieta E, et al. Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord. 2007 ; 104: 137-146
43. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003 ; 60: 1079-1088
44. Van Lieshout RJ, MacQueen GM. Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review. Br J Psychiatry. 2010 ; 196: 266-273
45. Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2007 ; 9: 413-425
46. Williamson D, Brown E, Perlis RH, Ahl J, Baker RW, Tohen M. Clinical relevance of depressive symptom improvement in bipolar I depressed patients. J Affect Disord. 2006 ; 92: 261-266
47. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009 ; 11: 225-255
48. Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010 ; 71: 150-162